3Stejnmctz A, Fenselau S, Schrezenmej RJ. Treatment of dyslipoproteinemia in the metabolic syndrome[J]. Exp Clin Endocrinol Diabetes,2001, 109(4) :S548-S559.
4Wajchenberg BL, Giannella Nero D, da Silva MER, et al. Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome[ J]. Horm Metab Res,2002, 34(11/12) :616-621.
5Chinali M, Devereux RB, Howard BV, et al. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome ( the Strong Heart Study) [ J]. Am J Cardiol,2004, 93 ( 1 ) :40-44.
6Davy BM, Melby CL. The effect of fiber-rach carbohydrates on features of Syndrome X[J]. J Am Diet Assoc ,2003,103 ( 1 ) : 86-96.
7Blair SN, Conelly JC. How much physical activity should be we do The ease for moderate amounts and intensity of physical activity [ J ]. Research Quarterly for Exercise and Sport, 1996,67 (2) : 193.
8Aellen R, Hollmann W, BouteHier V, et al. Effects of aerobic and anaerobic training on plasma lipoproteins [J ]. Int J Sports Med, 1993, 14 (7) :396400.
9Leibel RI, Rosenbaum M, Hirseh J. Changes in the energy expenditure resulting from altered body weight [J]. N Engl J Med, 1995, 332 (10) :621-628.
4Wisse BE.The inflammatory syndrome:the role of adipose tissue cytokines in metabolic disorders linked to obesity[J].J Am Soc Nephrol,2004,15:2792-2800.
5Isomaa B,Almgren P,Tuomi T,et al.Cardiovascular morbidity and mortality associated with the metabolic syndrome[J].Diabetes Care,2001,24:683-689.
6Pan C,Yang W,Jia W,et al.Management of Chinese patients with type 2 diabetes,1998-2006:the Diabcare-China surveys[J].Curr Med Res Opin,2009,25 (1):39-45.
7Abuissa H,Jones PG,Marso SP,et al.Angiotensinconverting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes:a metaanalysis of randomized clinical trials[J].J Am Coll Cardiol,2005,46 (5):821-826.
8Colhoun HM,Betteridge DJ,Durrington PN,et al.Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS):muhicentre randomised placebo-controlled trial[J].Lancet,2004,364(9435):685-696.
9Sidhaye A,Cheskin LJ.Pharmacologic treatment of obesity[J].Adv Psychosom Med,2006,27 (1):42-52.
10Nislanen LK,Lasksonen DE,Nyyssonen K,et al.Uric acid level as a risk factor for cardiovascular and all cause mortality in middle-aged men:a prospective cohort study[J].Arch Intern Med,2004,164 (14):1546-1551.
